Compounds > 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone
Page last updated: 2024-08-02 04:46:11

4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone

Description

4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone: structure [MeSH]

Cross-References

ID SourceID
PubMed CID6787155
CHEMBL ID443772
SCHEMBL ID13008066
MeSH IDM0060640

Synonyms (14)

Synonym
maiq
CHEMBL443772
[(5-amino-4-methylisoquinolin-1-yl)methylideneamino]thiourea
59261-39-1
4-methyl-5-aminoisoquinoline thiosemicarbazone
hydrazinecarbothioamide, 2-((5-amino-4-methyl-1-isoquinolinyl)methylene)-
4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone
maiq 1
SCHEMBL13008066
[(5-amino-4-methyl-1-isoquinolinyl)methylideneamino]thiourea
bdbm81247
[(5-amino-4-methyl-1-isoquinolyl)methyleneamino]thiourea
1-[(5-azanyl-4-methyl-isoquinolin-1-yl)methylideneamino]thiourea
cid_3035508

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1150329Antitumor activity against mouse S180A cells allografted in CD-1 mouse assessed as average survival at maximum effective dose administered qd for 6 days (Rvb = 12.6 +/- 0.6 days)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
ISSN: 0022-2623		Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID350249Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
ISSN: 1520-4804		Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID350248Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
ISSN: 1520-4804		Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1150331Inhibition of ribonucleoside-diphosphate reductase in rat hepatoma cells relative to 5-hydroxy-2-formylpyridine thiosemicarbazone1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
ISSN: 0022-2623		Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID350247Selectivity ratio of IC50 for human P-gp-negative KB-3-1 cells to human P-glycoprotein-expressing KBV1 cells2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
ISSN: 1520-4804		Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1150330Antitumor activity against mouse S180A cells allografted in CD-1 mouse assessed as average survival at maximum effective dose administered qd for 6 days relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
ISSN: 0022-2623		Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID1150328Toxicity in CD-1 mouse allografted with mouse S180A cells assessed as change in body weight at at maximum effective dose administered qd for 6 days (Rvb = 18.2%)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
ISSN: 0022-2623		Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID1150327Antitumor activity against mouse S180A cells allografted in CD-1 mouse assessed as dose required for maximum increase in mouse survival administered qd for 6 days1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
ISSN: 0022-2623		Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID1150332Inhibition of ribonucleoside-diphosphate reductase in rat hepatoma cells relative to 4-(m-amino)phenyl-2-formylpyridine thiosemicarbazone1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
ISSN: 0022-2623		Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (69.57)18.7374
1990's5 (21.74)18.2507
2000's2 (8.70)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
isatin
1
indoledioneEC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite		2009200915.0low000100
staurosporine
1
indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector		2009200915.0low000100
isatin beta-thiosemicarbazone
1
2009200915.0low000100
su 11248
1
monocarboxylic acid amide;
pyrroles		angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist		2009200915.0low000100
thioacetazone
1
2009200915.0low000100
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
1
2009200915.0low000100
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
adenine
2
6-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1988199035.0low011000
pyridoxal phosphate
2
methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1979198542.0low020000
caffeine
1
purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic		1999199925.0low001000
deferoxamine
1
acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore		1984198440.0low010000
9-(2-hydroxy-3-nonyl)adenine
2
1988199035.0low011000
hydroxyurea
9
one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent		1979199838.8medium081000
thymidine
1
pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite		1985198539.0low010000
edetic acid
1
ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector		1981198143.0low010000
cytidine diphosphate
2
cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite		1980198342.5low020000
guanazole
4
aromatic amine;
triazoles		antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor		1979198542.0medium040000
2'-deoxyadenosine triphosphate
1
2'-deoxyadenosine 5'-phosphate;
purine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite		1981198143.0low010000
vidarabine
1
beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic		1985198539.0low010000
platinum
1
elemental platinum;
nickel group element atom;
platinum group metal atom		1979197945.0low010000
daunorubicin
1
aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite		2002200222.0low000100
chlorodiphenyl (54% chlorine)
1
1999199925.0low001000
2-amino-3-methylimidazo(4,5-f)quinoline
1
imidazoquinolinecarcinogenic agent1984198440.0low010000
thymidine 5'-triphosphate
1
pyrimidine 2'-deoxyribonucleoside 5'-triphosphate;
thymidine phosphate		Escherichia coli metabolite;
mouse metabolite		1981198143.0low010000
triazoles
2
1,2,3-triazole1984198539.5low020000
2'-fluoro-2'-deoxyadenosine
1
1985198539.0low010000
2,3-dihydro-1h-imidazo(1,2-b)pyrazole
7
1980199837.4high052000
fludarabine
1
purine nucleoside1985198539.0low010000
nadp
1
1988198836.0low010000
rhodamine 123
1
organic cation;
xanthene dye		fluorochrome2002200222.0low000100
2-formylpyridine thiosemicarbazone
1
1984198440.0low010000
1-formylisoquinoline thiosemicarbazone
3
1980198840.0high030000
mocetinostat
1
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		1984198440.0low010000
sepharose
1
1985198539.0low010000
deoxyguanosine
1
purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1985198539.0low010000
deoxyguanosine triphosphate
1
deoxyguanosine phosphate;
guanyl deoxyribonucleotide;
purine 2'-deoxyribonucleoside 5'-triphosphate		Arabidopsis thaliana metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		1981198143.0low010000
inosine
3
inosines;
purines D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite		1979198542.3low030000
inosine dialdehyde
3
1979198542.3high030000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Cancer of Colon0
1
1990199034.0low001000
Cancer of Lung0
1
1977197747.0low010000
Carcinoma, Ehrlich Tumor0
3
1979198144.0medium030000
Colonic Neoplasms0
1
1990199034.0low001000
Experimental Hepatoma0
1
1980198044.0low010000
Experimental Leukemia0
1
1977197747.0low010000
Experimental Neoplasms0
2
1977198344.0low020000
Germinoblastoma0
1
1983198341.0low010000
Leucocythaemia0
1
1998199826.0low001000
Leukemia0
1
1998199826.0low001000
Leukemia L 12100
7
1977199937.1high052000
Lung Neoplasms0
1
1977197747.0low010000
Lymphoma0
1
1983198341.0low010000
Malignant Melanoma0
1
1977197747.0low010000
Melanoma0
1
1977197747.0low010000
Sarcoma 1800
2
1976197747.5low020000

Interactions (1)

ArticleYear
Schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia.
Cancer treatment reports, , Volume: 63, Issue:3		1979